CG
GNMK

Cutler Group’s GenMark Diagnostics, Inc GNMK Stock Holding History

Cutler Group’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4,504
Closed -$107K – 6750
2021
Q1 		$107K Buy
4,504
+3,800
+540% +$70.6K 0.01% 1725
2020
Q4 		$10K Buy
704
+204
+41% +$2.7K ﹤0.01% 3240
2020
Q3 		$7K Sell
500
-4,160
-89% -$63.6K ﹤0.01% 3305
2020
Q2 		$68K Buy
+4,660
New +$47.3K ﹤0.01% 1547
2017
Q4 		– Sell
-1,052
Closed -$10K – 6330
2017
Q3 		$10K Sell
1,052
-412
-28% -$4.28K ﹤0.01% 3843
2017
Q2 		$17K Buy
1,464
+971
+197% +$12.4K ﹤0.01% 3621
2017
Q1 		$6K Sell
493
-927
-65% -$11.2K ﹤0.01% 4638
2016
Q4 		$17K Buy
1,420
+1,320
+1,320% +$15.7K ﹤0.01% 3663
2016
Q3 		$1K Buy
+100
New +$965 ﹤0.01% 6415

Cutler Group's GNMK Position: Q2 2021 in Review

Cutler Group sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2021, closing a stake of 4,504 shares — an estimated $107K sold.

Cutler Group first reported a position in GNMK in Q3 2016 and held it in 9 quarters. The position peaked at $107K in Q1 2021. 0 funds tracked by Wall St. Rank hold GNMK as of Q2 2021.

  • Cutler Group reported no remaining GenMark Diagnostics, Inc position as of Q2 2021 after selling out during the quarter.
  • Cutler Group sold 4,504 GenMark Diagnostics, Inc shares in Q2 2021, an estimated $107K.
  • Cutler Group first reported a position in GenMark Diagnostics, Inc in Q3 2016 and held it in 9 quarters.
  • Cutler Group's GenMark Diagnostics, Inc position peaked at $107K in Q1 2021.
  • 0 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2021.

Based on Cutler Group's 13F filing for Q2 2021, filed 19 Jul 2021.